Anzeige
Mehr »
Montag, 09.03.2026 - Börsentäglich über 12.000 News
Verdoppelt - und noch nicht am Ziel? Dieser Rohstoff-Explorer profitiert vom Antimon-Boom
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
298 Leser
Artikel bewerten:
(0)

iNewswire: POMS Announces the Release of POMSnet R500.3 With HTML5 User Interface and Touch Screen-Enabled, Web-Based Manufacturing Execution System

WASHINGTON, DC / ACCESSWIRE / December 5, 2019 / Washington, D.C.-based POMS Corporation announces the next major release of POMSnet, R500.3. POMSnet R500.3 is an industry-leading, cloud-enabled, HTML5 manufacturing execution system. This release provides enhanced user experience by leveraging HTML5 technologies for the most comprehensive, commercial, off-the-shelf (COTS) MES product available to the life sciences industry. POMSnet MES enables life science manufacturers (i.e., pharma, biotech, medical device, cell/gene therapy) to implement regulatory-compliant, paperless manufacturing workflows for batch records and product release. POMSnet R500.3 includes a user interface style update with responsive actions, including touch screen enabled hand gestures, zooming, and finger scrolling. Browser compatibility is greatly increased and now allows HTML5-enabled browser selection to run the web-based application. Mobile device delivery and responsive technology fit POMSnet R500.3 onto any mobile device screen.

POMSnet R500.3 HTML5 User Interface Screen Images

POMS Corp. Release New HTML5 Version of POMSnet Manufacturing Execution System for Life Science Industry

In addition to the full HTML5 update of the product, POMS has also added other significant features and enhancements such as the following:

  • Dispensing Dashboard displays the overall batch details (i.e., order, batch, product, lot, status, dispense times and exceptions) and dispenses details (i.e., dispense details for each Bill of Material line item, such as containers dispensed, quantities, times, locations and scales).
  • Query Manager allows users to define and create any database query report against the POMS database. All the data is exposed for user query and reporting. This will also allow POMS to continue to add standard product reports/queries in ongoing releases based on customer requests. This release provided 70 standard out-of-the-box query reports.
  • An enhanced version of Specification Manager to support faster recipe batch record management and changes. In addition, with the HTML5 updates, batch record recipes will now support advanced instructional text such as links to pictures, videos, and advanced text formatted instructions. Recipe procedure function charts now also support graphic objects with configurable dynamic behaviors.

Life science manufacturers are regulated by regulatory authorities and current good manufacturing practices cGMP in the production process of pharmaceutical and biotech medicines and required to follow safety procedures. Companies have traditionally sought paper forms to document the production process recipe and specifications followed during manufacturing. With POMSnet R500.3 the manufacturing workflow can be implemented, monitored, and controlled by the manufacturing execution system to ensure regulatory guidelines are followed, best practices are implemented, and cGMP is enforced.

POMS Corporation, based out of Washington, D.C., is an MES software provider that counts five of the world's 10 largest pharmaceutical companies among its clients.

"Short term, our goal is to get this technology out in front of our customers so they can recognize the benefits quickly," said Patrick Nazzaro, General Manager at POMS. "Longer term, the technology offers us the capability to do more rapid agile development and release the extensive, feature-rich functionality the industry demands."

What pharmaceutical experts are saying about POMSnet R500.3 on LinkedIn

POMSnet R500.3 release is available now by contacting POMS Corporation.

About POMS Corporation

A Washington, D.C.-based provider of Manufacturing Execution System software for regulated life science companies. POMS provides web-based and cloud-based MES solutions for life science manufacturers ensuring FDA compliance and 21 CFR Part 11 electronic signatures for electronic batch records. POMS Corporation is a company in the Perseus Operating Group with the parent company Constellation Software Inc. headquartered in Toronto, Canada, and traded on the Toronto Stock exchange with $3.1 billion revenue and 16,000 employees worldwide.

Media Contacts
Darrell Tanner
POMS
703-574-9900
Darrell.tanner@poms.com

SOURCE: POMS Corporation



View source version on accesswire.com:
https://www.accesswire.com/569202/POMS-Announces-the-Release-of-POMSnet-R5003-With-HTML5-User-Interface-and-Touch-Screen-Enabled-Web-Based-Manufacturing-Execution-System

© 2019 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.